Novartis BP drug sees approval in Europe

Share this article:
The European Commission approved Novartis' Rasilez (aliskiren) for use in the European Union.

The approval follows an FDA endorsement earlier this year in the US, where the drug is sold as Tekturna. It's also approved in Switzerland.

Analysts have estimated peak sales of between $2.5 billion to $3.5 billion for the Novartis pill, which was co-developed by Swiss biotech company Speedel.

When used alone, Rasilez demonstrates greater blood pressure lowering than other commonly-used blood pressure medicines, like ACE inhibitors and certain diuretics. When added to existing therapy, it provides additional blood pressure lowering, the company said in a statement.

Novartis said nearly a billion people around the world have high blood pressure, and almost 70% do not reach their blood pressure goal.

Tekturna targets renin, an enzyme responsible for triggering a process that can contribute to the condition.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?